A clinical study of varlitinib in the patients with advanced or metastatic hepatocellular carcinoma (HCC)

Trial Profile

A clinical study of varlitinib in the patients with advanced or metastatic hepatocellular carcinoma (HCC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Varlitinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Sep 2017 New trial record
    • 07 Sep 2017 According to an ASLAN Pharmaceuticals media release, National University Cancer Institute, Singapore (NCIS), a member of the National University Health System is associated with this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top